Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Lannett Company, Inc.    LCI

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 654 M
EBIT 2017 242 M
Net income 2017 10,2 M
Debt 2017 798 M
Yield 2017 -
Sales 2018 647 M
EBIT 2018 221 M
Net income 2018 80,7 M
Debt 2018 772 M
Yield 2018 -
P/E ratio 2017 417,33
P/E ratio 2018 12,65
EV / Sales2017 2,11x
EV / Sales2018 2,09x
Capitalization 583 M
More Financials
Company
Lannett Co., Inc. engages in the development, manufacture, market, and distribution of generic pharmaceutical products.Its pharmaceutical products are distributed to drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers,... 
Sector
Pharmaceuticals
Calendar
08/23Earnings Release
More about the company
Surperformance© ratings of Lannett Company, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on LANNETT COMPANY, INC.
08/09 LANNETT : Announces Preliminary Fiscal 2017 Fourth Quarter and Full Year Financi..
08/08 LANNETT : Announces Preliminary Fiscal 2017 Fourth-Quarter And Full-Year Financi..
08/01 LANNETT : To Present At The Canaccord Genuity 37th Annual Growth Conference On A..
07/19 LANNETT CO INC : Change in Directors or Principal Officers, Financial Statements..
07/18 LANNETT : Appoints Samuel H. Israel As General Counsel
07/17 LANNETT COMPANY, INC. : Corporate News Blog - Lannett Co. Receives Approval for ..
07/17 LANNETT : Appoints Samuel H. Israel As General Counsel
07/14 LANNETT : Receives Approval For Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL
06/28 LANNETT COMPANY, INC. : Corporate News Blog - Lannett Receives Approval for Addi..
06/26 LANNETT : Receives Approval For Additional Dosage Strengths Of Hydrocodone Bitar..
More news
Sector news : Pharmaceuticals - NEC
08/18DJCorrection to Biogen Treads Tricky Path Between Politicians, Investors Articl..
08/18DJMERCK AND : Scientists, Out $12 Million, Sue Delaware Over Seizure of Their Stoc..
08/18DJASTRAZENECA : FDA Approves AstraZeneca's Ovarian Cancer Treatment Lynparza Table..
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/17 Drugmaker Hikma trims sales forecasts, shares fall
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,2 $
Spread / Average Target 67%
EPS Revisions
Managers
NameTitle
Arthur P. Bedrosian Chief Executive Officer & Director
Jeffrey Farber Chairman
Martin P. Galvan CFO, Treasurer & Vice President-Finance
Robert Ehlinger Chief Information Officer & VP-logistics
Kristin A. Arnold Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
LANNETT COMPANY, INC.583
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554
MERCK AND COMPANY4.45%167 705